{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:13:29Z","timestamp":1782454409361,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03815-w","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T15:59:01Z","timestamp":1738425541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of Spironolactone in treating patients with acne vulgaris: a systematic review and meta-analysis of 1,086 patients"],"prefix":"10.1007","volume":"317","author":[{"given":"Mohamed","family":"Farrag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Abo Elnaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3571-7708","authenticated-orcid":false,"given":"Mohamed A.","family":"Alsaied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Karam Allah","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Elettreby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"3815_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjd.13462","volume":"172","author":"JKL Tan","year":"2015","unstructured":"Tan JKL, Bhate K (2015) A global perspective on the epidemiology of acne. Br J Dermatol 172:3\u201312. https:\/\/doi.org\/10.1111\/bjd.13462","journal-title":"Br J Dermatol"},{"key":"3815_CR2","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.bbrep.2023.101578","volume":"36","author":"M Vasam","year":"2023","unstructured":"Vasam M, Korutla S, Bohara RA (2023) Acne vulgaris: a review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochem Biophys Rep 36:101578. https:\/\/doi.org\/10.1016\/j.bbrep.2023.101578","journal-title":"Biochem Biophys Rep"},{"key":"3815_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.det.2011.09.001","volume":"30","author":"S Knutsen-Larson","year":"2012","unstructured":"Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP (2012) Acne Vulgaris: Pathogenesis, Treatment, and needs Assessment. Dermatol Clin 30:99\u2013106. https:\/\/doi.org\/10.1016\/j.det.2011.09.001","journal-title":"Dermatol Clin"},{"key":"3815_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/CCID.S137794","volume":"11","author":"MA Rocha","year":"2018","unstructured":"Rocha MA, Bagatin E (2018) Adult-onset acne: prevalence, impact, and management challenges. CCID Volume 11:59\u201369. https:\/\/doi.org\/10.2147\/CCID.S137794","journal-title":"CCID Volume"},{"key":"3815_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1046\/j.1523-1747.2002.00613.x","volume":"119","author":"W Chen","year":"2002","unstructured":"Chen W, Thiboutot D, Zouboulis CC (2002) Cutaneous androgen metabolism: Basic Research and clinical perspectives. J Invest Dermatology 119:992\u20131007. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.00613.x","journal-title":"J Invest Dermatology"},{"key":"3815_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4103\/0019-5154.74539","volume":"55","author":"J Golchai","year":"2010","unstructured":"Golchai J, Khani S, Heidarzadeh A et al (2010) Comparison of anxiety and depression in patients with acne vulgaris and healthy individuals. Indian J Dermatol 55:352. https:\/\/doi.org\/10.4103\/0019-5154.74539","journal-title":"Indian J Dermatol"},{"key":"3815_CR7","doi-asserted-by":"publisher","first-page":"21084","DOI":"10.1038\/s41598-023-48182-6","volume":"13","author":"ASM Morshed","year":"2023","unstructured":"Morshed ASM, Noor T, Uddin Ahmed MA et al (2023) Understanding the impact of acne vulgaris and associated psychological distress on self-esteem and quality of life via regression modeling with CADI, DLQI, and WHOQoL. Sci Rep 13:21084. https:\/\/doi.org\/10.1038\/s41598-023-48182-6","journal-title":"Sci Rep"},{"key":"3815_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clindermatol.2004.03.012","volume":"22","author":"AR Shalita","year":"2004","unstructured":"Shalita AR (2004) Acne: clinical presentations. Clin Dermatol 22:385\u2013386. https:\/\/doi.org\/10.1016\/j.clindermatol.2004.03.012","journal-title":"Clin Dermatol"},{"key":"3815_CR9","volume-title":"Acne Vulgaris","author":"AH Sutaria","year":"2024","unstructured":"Sutaria AH, Masood S, Saleh HM, Schlessinger J (2024) Acne Vulgaris. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"3815_CR10","doi-asserted-by":"publisher","unstructured":"Eichenfield DZ, Sprague J, Eichenfield LF (2021) Management of Acne Vulgaris: a review. JAMA 326:2055. https:\/\/doi.org\/10.1001\/jama.2021.17633","DOI":"10.1001\/jama.2021.17633"},{"key":"3815_CR11","doi-asserted-by":"publisher","first-page":"E430","DOI":"10.1503\/cmaj.090374","volume":"183","author":"J Kraft","year":"2011","unstructured":"Kraft J, Freiman A (2011) Management of acne. Can Med Assoc J 183:E430\u2013E435. https:\/\/doi.org\/10.1503\/cmaj.090374","journal-title":"Can Med Assoc J"},{"key":"3815_CR12","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2165\/00003495-200464210-00002","volume":"64","author":"B Dreno","year":"2004","unstructured":"Dreno B (2004) Topical antibacterial therapy for Acne Vulgaris. Drugs 64:2389\u20132397. https:\/\/doi.org\/10.2165\/00003495-200464210-00002","journal-title":"Drugs"},{"key":"3815_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40257-017-0267-z","volume":"18","author":"A Bienenfeld","year":"2017","unstructured":"Bienenfeld A, Nagler AR, Orlow SJ (2017) Oral antibacterial therapy for Acne Vulgaris: an evidence-based review. Am J Clin Dermatol 18:469\u2013490. https:\/\/doi.org\/10.1007\/s40257-017-0267-z","journal-title":"Am J Clin Dermatol"},{"key":"3815_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/IBPC.S13783","volume":"6","author":"JW Funder","year":"2013","unstructured":"Funder JW (2013) Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 6:129\u2013138. https:\/\/doi.org\/10.2147\/IBPC.S13783","journal-title":"Integr Blood Press Control"},{"key":"3815_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA (2005) Pharmacokinetics and pharmacodynamics of Mineralocorticoid Blocking agents and their effects on Potassium Homeostasis. Heart Fail Rev 10:23\u201329. https:\/\/doi.org\/10.1007\/s10741-005-2345-1","journal-title":"Heart Fail Rev"},{"key":"3815_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","volume":"18","author":"AM Layton","year":"2017","unstructured":"Layton AM, Eady EA, Whitehouse H et al (2017) Oral spironolactone for Acne Vulgaris in Adult females: a hybrid systematic review. Am J Clin Dermatol 18:169\u2013191. https:\/\/doi.org\/10.1007\/s40257-016-0245-x","journal-title":"Am J Clin Dermatol"},{"key":"3815_CR17","first-page":"16","volume":"2","author":"TL Ebede","year":"2009","unstructured":"Ebede TL, Arch EL, Berson D (2009) Hormonal treatment of acne in women. J Clin Aesthet Dermatol 2:16\u201322","journal-title":"J Clin Aesthet Dermatol"},{"key":"3815_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/ced.14340","volume":"45","author":"TN Searle","year":"2020","unstructured":"Searle TN, Al-Niaimi F, Ali FR (2020) Spironolactone in dermatology: uses in acne and beyond. Clin Exp Dermatol 45:986\u2013993. https:\/\/doi.org\/10.1111\/ced.14340","journal-title":"Clin Exp Dermatol"},{"key":"3815_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijwd.2020.05.002","volume":"6","author":"Y Wang","year":"2020","unstructured":"Wang Y, Lipner SR (2020) Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration. Int J Women\u2019s Dermatology 6:272\u2013276. https:\/\/doi.org\/10.1016\/j.ijwd.2020.05.002","journal-title":"Int J Women\u2019s Dermatology"},{"key":"3815_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/1346-8138.16637","volume":"50","author":"ST Rehan","year":"2023","unstructured":"Rehan ST, Khan Z, Abbas S et al (2023) Role of topical spironolactone in the treatment of acne: a systematic review of clinical trials\u2014does this therapy open a path towards favorable outcomes? J Dermatol 50:166\u2013174. https:\/\/doi.org\/10.1111\/1346-8138.16637","journal-title":"J Dermatol"},{"key":"3815_CR21","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. https:\/\/doi.org\/10.1136\/bmj.n71. BMJ n71","DOI":"10.1136\/bmj.n71"},{"key":"3815_CR22","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane Handbook for Systematic Reviews of Interventions, 1st edn. Wiley","DOI":"10.1002\/9781119536604"},{"key":"3815_CR23","unstructured":"EndNote| The Best Citation & Reference Management Tool. In: EndNote. https:\/\/endnote.com\/. Accessed 19 Sep 2023"},{"key":"3815_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"3815_CR25","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. https:\/\/doi.org\/10.1136\/bmj.l4898. BMJ l4898","DOI":"10.1136\/bmj.l4898"},{"key":"3815_CR26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"3815_CR27","unstructured":"R Core Team (2021) R: a Language and. Environment for Statistical Computing"},{"key":"3815_CR28","unstructured":"PlotDigitizer In: PlotDigitizer. https:\/\/www.plotdigitizer.com. Accessed 28 Apr 2024"},{"key":"3815_CR29","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions https:\/\/training.cochrane.org\/handbook. Accessed 5 Jul 2024"},{"key":"3815_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"3815_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","volume":"111","author":"A Goodfellow","year":"1984","unstructured":"Goodfellow A, Alaghband-Zadeh J, Carter G et al (1984) Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 111:209\u2013214. https:\/\/doi.org\/10.1111\/j.1365-2133.1984.tb04045.x","journal-title":"Br J Dermatol"},{"key":"3815_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","volume":"115","author":"MF Muhlemann","year":"1986","unstructured":"Muhlemann MF, Carter GD, Cream JJ, Wise P (1986) Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 115:227\u2013232. https:\/\/doi.org\/10.1111\/j.1365-2133.1986.tb05722.x","journal-title":"Br J Dermatol"},{"key":"3815_CR33","first-page":"84","volume":"68","author":"A Hatwal","year":"1988","unstructured":"Hatwal A, Bhatt RP, Agrawal JK et al (1988) Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol 68:84\u201387","journal-title":"Acta Derm Venereol"},{"key":"3815_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/09546634.2010.488260","volume":"23","author":"BM Afzali","year":"2012","unstructured":"Afzali BM, Yaghoobi E, Yaghoobi R et al (2012) Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial. J Dermatological Treat 23:21\u201325. https:\/\/doi.org\/10.3109\/09546634.2010.488260","journal-title":"J Dermatological Treat"},{"key":"3815_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.colsurfb.2016.05.042","volume":"146","author":"HR Kelidari","year":"2016","unstructured":"Kelidari HR, Saeedi M, Hajheydari Z et al (2016) Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: a randomized, double-blind, prospective trial. Colloids Surf B 146:47\u201353. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.05.042","journal-title":"Colloids Surf B"},{"key":"3815_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/ejdv.ejdv_36_18","volume":"39","author":"E Attwa","year":"2019","unstructured":"Attwa E, Ibrahim AS, Abd El-Halim M, Mahmoud H (2019) Efficacy and safety of topical spironolactone 5% gel versus placebo in the treatment of acne vulgaris. Egypt J Dermatol Venerol 39:89. https:\/\/doi.org\/10.4103\/ejdv.ejdv_36_18","journal-title":"Egypt J Dermatol Venerol"},{"key":"3815_CR37","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/1346-8138.15559","volume":"47","author":"M Patiyasikunt","year":"2020","unstructured":"Patiyasikunt M, Chancheewa B, Asawanonda P et al (2020) Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: a randomized, double\u2010blind, placebo\u2010controlled trial. J Dermatol 47:1411\u20131416. https:\/\/doi.org\/10.1111\/1346-8138.15559","journal-title":"J Dermatol"},{"key":"3815_CR38","doi-asserted-by":"publisher","unstructured":"Noaimi A, Al-Saadi SR (2021) Treatment of Acne Vulgaris by Topical Spironolactone Solution compared with clindamycin solution. https:\/\/doi.org\/10.7759\/cureus.17606. Cureus","DOI":"10.7759\/cureus.17606"},{"key":"3815_CR39","doi-asserted-by":"publisher","unstructured":"Santer M, Lawrence M, Renz S et al (2023) Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. https:\/\/doi.org\/10.1136\/bmj-2022-074349. BMJ e074349","DOI":"10.1136\/bmj-2022-074349"},{"key":"3815_CR40","doi-asserted-by":"publisher","first-page":"adv26002","DOI":"10.2340\/actadv.v104.26002","volume":"104","author":"B Dr\u00e9no","year":"2024","unstructured":"Dr\u00e9no B, Nguyen J-M, Hainaut E et al (2024) Efficacy of Spironolactone compared with doxycycline in Moderate Acne in Adult females: results of the Multicentre, Controlled, Randomized, double-blind prospective and Parallel Female Acne Spironolactone vs doxyCycline efficacy (FASCE) study. Acta Derm Venereol 104:adv26002. https:\/\/doi.org\/10.2340\/actadv.v104.26002","journal-title":"Acta Derm Venereol"},{"key":"3815_CR41","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1002\/hsr2.317","volume":"4","author":"A Ayatollahi","year":"2021","unstructured":"Ayatollahi A, Samadi A, Bahmanjahromi A, Robati RM (2021) Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: a pilot study. Health Sci Rep 4:e317. https:\/\/doi.org\/10.1002\/hsr2.317","journal-title":"Health Sci Rep"},{"key":"3815_CR42","first-page":"101","volume":"29","author":"M Sanai","year":"2019","unstructured":"Sanai M, Shaukat S, Ghias A et al (2019) Efficacy and safety of spironolactone in moderate to severe acne in females. J Pakistan Association Dermatologists 29:101\u2013109","journal-title":"J Pakistan Association Dermatologists"},{"key":"3815_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","volume":"30","author":"K Sato","year":"2006","unstructured":"Sato K, Matsumoto D, Iizuka F et al (2006) Anti-androgenic therapy using oral spironolactone for Acne Vulgaris in asians. Aesth Plast Surg 30:689\u2013694. https:\/\/doi.org\/10.1007\/s00266-006-0081-0","journal-title":"Aesth Plast Surg"},{"key":"3815_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","volume":"19","author":"A Yemisci","year":"2005","unstructured":"Yemisci A, Gorgulu A, Piskin S (2005) Effects and side-effects of spironolactone therapy in women with acne. Acad Dermatol Venereol 19:163\u2013166. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01072.x","journal-title":"Acad Dermatol Venereol"},{"key":"3815_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clindermatol.2009.03.012","volume":"28","author":"C Dessinioti","year":"2010","unstructured":"Dessinioti C, Katsambas AD (2010) The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol 28:2\u20137. https:\/\/doi.org\/10.1016\/j.clindermatol.2009.03.012","journal-title":"Clin Dermatol"},{"key":"3815_CR46","first-page":"2123","volume":"69","author":"S Feldman","year":"2004","unstructured":"Feldman S, Careccia RE, Barham KL, Hancox J (2004) Diagnosis and treatment of acne. Am Fam Physician 69:2123\u20132130","journal-title":"Am Fam Physician"},{"key":"3815_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0190-9622(91)70034-Y","volume":"24","author":"JC Shaw","year":"1991","unstructured":"Shaw JC (1991) Spironolactone in dermatologic therapy. J Am Acad Dermatol 24:236\u2013243. https:\/\/doi.org\/10.1016\/0190-9622(91)70034-Y","journal-title":"J Am Acad Dermatol"},{"key":"3815_CR48","doi-asserted-by":"publisher","unstructured":"Brown J, Farquhar C, Lee O et al (2009) Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne. https:\/\/doi.org\/10.1002\/14651858.CD000194.pub2. Cochrane Database of Systematic Reviews","DOI":"10.1002\/14651858.CD000194.pub2"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03815-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03815-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T15:59:08Z","timestamp":1738425548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03815-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3815"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03815-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The article is a systematic review and meta-analysis of existing studies, using no new data from human participants. Therefore, no ethical approval or patient consent was required. The review followed the PRISMA guidelines to maintain transparency, integrity, and ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}